[144] BridgeBio Pharma, Inc. SEC Filing

Rhea-AI Filing Summary

BridgeBio Pharma (BBIO) Form 144 filing: The filing notifies a proposed sale of 17,353 shares of common stock through Morgan Stanley Smith Barney LLC on 08/18/2025 with an aggregate market value of $871,722.75. The filing reports 191,168,504 shares outstanding. The shares to be sold were issued as restricted stock in four grants: 4,757 shares acquired 11/16/2023, 3,048 shares acquired 08/16/2023, 6,264 shares acquired 02/16/2024, and 3,284 shares acquired 05/16/2024. The filer reports nothing to report for securities sold in the past three months and affirms they do not possess undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine Form 144 disclosing proposed insider sale via broker; details of grant dates and share counts are provided.

The filing documents a proposed sale of 17,353 common shares on 08/18/2025 through Morgan Stanley Smith Barney LLC with an aggregate market value of $871,722.75. The notice lists four restricted-stock acquisitions spanning 08/16/2023 to 02/16/2024 and confirms no sales in the past three months. This is a regulatory notification under Rule 144 and provides the necessary acquisition and broker details investors and compliance teams use to track potential insider selling activity.

Compliance/Risk Analyst

TL;DR: Filing appears procedurally complete for Rule 144 compliance and includes the signer’s attestation about material nonpublic information.

The notice names the executing broker and supplies acquisition dates and share amounts for the restricted grants being sold. It also contains the required attestation that the seller does not know of undisclosed material adverse information, and states there were no reportable sales in the prior three months. From a compliance perspective, the form contains the core elements regulators expect for a proposed Rule 144 sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	17353	871722.75	191168504	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/16/2023	Restricted Stock	ISSUER			4757	11/16/2023	Not Applicable
Common	08/16/2023	Restricted Stock	ISSUER			3048	08/16/2023	Not Applicable
Common	02/16/2024	Restricted Stock	ISSUER			6264	02/16/2024	Not Applicable
Common	05/16/2024	Restricted Stock	ISSUER			3284	05/16/2024	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)